John McDermott

John McDermott serves as the CEO of Vascular Therapies since 2019 and is a board member at Auxetics and Paragonix Technologies, Inc. Previously, John held the role of CEO and served on the Board of Directors at Endologix from 2008 to 2018, during which the company was acquired by Deerfield. John also contributed as a board member at Entellus Medical and Angiotech Pharmaceuticals, both of which were acquired by Stryker and Vivo Capital, respectively. Earlier in John's career, notable positions included leadership roles at CR Bard and IMPRA, Inc., culminating in an MBA from Western International University and a BS in Finance from Arizona State University.